ArchiMed acquires neurodiagnostic devices provider Natus Medical
Natus shareholders received $33.50 in cash for each share of company common stock.

Natus shareholders received $33.50 in cash for each share of company common stock.
The new simulator is developed by medical simulation training company VirtaMed.
The molecular SARS-CoV-2 test relies on the RHINOstic Automated Nasal Swab from Rhinostics.
The company’s fourth quarter worldwide revenue declined by 1% on a reported basis to $8.09bn.
The Sleepio app leverages an AI algorithm to offer customised digital cognitive behavioural therapy for insomnia (CBT-I).
Mainz will leverage Dante’s various established commercial channels to introduce ColoAlert in Italy and the UAE.
The SARS-CoV-2 Ag Ultra Test can deliver results in five minutes, allowing clinicians to begin treatments faster.
The test identified around 79% of early-stage bowel cancers in a primary care trial.
p-tau MAA is expected to provide researchers with an additional tool for Alzheimer’s and brain health studies.
Thank you for subscribing to Medical Device Network